Anavex to Present Data for ANAVEX 2-73 at Society for Neuroscience 2013 Annual Meeting

New York, NY — October 29, 2013 — Anavex Life Sciences Corp. (OTCQB: AVXL) today announced that Tangui Maurice, PhD, CNRS Research Director, Head of Team 2 ‘Endogenous Neuroprotection in Neurodegenerative Diseases’, at the University of Montpellier and INSERM, will be presenting new data supporting the investigational compound ANAVEX 2-73 as a potential therapeutic for…

Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73 for Alzheimer’s Disease

New York, NY — October 22, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that the current issue of the peer-reviewed scientific journal PLOS ONE explains that sigma-1 receptor (Sig-1R) activity is involved in cellular survival by regulating and stabilizing a key cell stress sensor.  These findings may explain…